Teva Pharmaceutical Industries Ltd (TEVA) Receives New Coverage from Analysts at OTR Global
Equities researchers at OTR Global began coverage on shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) in a research report issued on Thursday. The firm set a “positive” rating on the stock.
A number of other equities research analysts also recently commented on the company. Mizuho reaffirmed a “buy” rating and set a $64.00 target price on shares of Teva Pharmaceutical Industries in a report on Monday. Leerink Swann reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Friday, September 23rd. Oppenheimer Holdings Inc. set a $66.00 target price on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Monday, September 12th. TheStreet downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Friday, September 9th. Finally, RBC Capital Markets set a $71.00 target price on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Sunday, September 11th. Seven analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $67.54.
Teva Pharmaceutical Industries (NYSE:TEVA) traded down 3.12% during midday trading on Thursday, hitting $47.16. 3,535,883 shares of the stock traded hands. The company has a 50-day moving average of $51.64 and a 200-day moving average of $53.00. The stock has a market cap of $43.10 billion, a PE ratio of 31.50 and a beta of 0.82. Teva Pharmaceutical Industries has a 12 month low of $47.14 and a 12 month high of $66.55.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, topping the Zacks’ consensus estimate of $1.20 by $0.05. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.86 billion. During the same period last year, the firm earned $1.43 EPS. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. On average, equities research analysts anticipate that Teva Pharmaceutical Industries will post $5.26 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Monday, August 22nd were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 2.79%. The ex-dividend date of this dividend was Thursday, August 18th.
A number of institutional investors have recently bought and sold shares of TEVA. Flow Traders U.S. LLC purchased a new position in Teva Pharmaceutical Industries during the first quarter valued at about $105,000. Sharkey Howes & Javer raised its position in Teva Pharmaceutical Industries by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock valued at $101,000 after buying an additional 358 shares during the last quarter. Hudock Capital Group LLC raised its position in Teva Pharmaceutical Industries by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock valued at $103,000 after buying an additional 564 shares during the last quarter. WFG Advisors LP raised its position in Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock valued at $104,000 after buying an additional 256 shares during the last quarter. Finally, Kistler Tiffany Companies LLC raised its position in Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock valued at $107,000 after buying an additional 64 shares during the last quarter.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related stocks with our FREE daily email newsletter.